Patents by Inventor Myeong Hee Jang

Myeong Hee Jang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient
    Patent number: 9388223
    Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: July 12, 2016
    Assignee: Antibody and Receptor Therapeutics Co., Ltd.
    Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
  • Myostatin Inhibitor Comprising Extracellular Water-Soluble Domains of DLK1 As Active Ingredient
    Publication number: 20150030595
    Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 29, 2015
    Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
  • Humanized anti-tag-72 monoclonal antibodies
    Patent number: 8119132
    Abstract: The present invention relates to humanized antibodies specific to a tumor-associated glycoprotein, TAG-72, and anticancer compositions comprising the humanized antibodies. In detail, the present invention relates to a humanized antibody which has enhanced antigen binding affinity by mutating a heavy chain of a humanized antibody PXA/HzK specific for TAG-72, an antibody which is prepared by replacing a light chain of the humanized antibody with a human light chain, and anticancer compositions including the antibodies.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: February 21, 2012
    Assignee: Korea Research Institute of Bioscience and Biotech
    Inventors: Hyo Jeong Hong, Sang Jick Kim, Sun Ok Yoon, Myeong Hee Jang, Keun Soo Kim, Tae Sup Lee, Chang Woon Choi
  • Humanized Anti-Tag-72 Monoclonal Antibodies
    Publication number: 20080279847
    Abstract: The present invention relates to humanized antibodies specific to a tumor associated glycoprotein, TAG-72, and anticancer compositions comprising the humanized antibodies. In detail, the present invention relates to a humanized antibody which has enhanced antigen binding affinity by mutating a heavy chain of a humanized antibody PXA/HzK specific for TAG-72, an antibody which is prepared by replacing a light chain of the humanized antibody with a human light chain, and anticancer compositions including the antibodies.
    Type: Application
    Filed: May 6, 2005
    Publication date: November 13, 2008
    Inventors: Hyo Jeong Hong, Sang Jick Kim, Sun Ok Yoon, Myeong Hee Jang, Keun Soo Kim, Tae Sup Lee, Chang Woon Choi